Considerable evidence from both clinical and experimental studies suggests that androgen receptor variants, particularly androgen receptor variant 7 (AR-V7), are critical in the induction of resistance to enzalutamide and abiraterone. In this study, we investigated the role of AR-V7 in the cross-resistance of enzalutamide and abiraterone and examined if inhibition of AR-V7 can improve abiratero...

Remote sensing precipitation products provide rich data for ungauged basins. Evaluating the accuracy and detection capability of remote is crucial before application. In this study, an index system in terms quantitative differences, capturing capacity distribution was constructed to evaluate three products, TRMM 3B42 V7, GPM IMERGE Final CMORPH V1.0, at various temporal spatial scales on Tibeta...

Prostate cancer continues to be the most common non-cutaneous malignancy afflicting men in developed countries [1]. Although surgery or radiotherapy for the primary disease appears be curative at the time of initial treatment, upward of 25% of men will have metastatic or residual disease (ACS Facts and Figures 2015). Since the advent of prostate-specific antigen assays, the recurrence of the ca...

Ligation of the V7 (CD101) molecule on T cells with anti-V7 mAb blocks TCR/CD3-induced proliferation by inhibiting IL-2 transcription. To explore the basis for this observation, we analyzed the effects of V7 ligation on CD3/TCR-induced changes in intracellular free Ca2+ and Ca2+-dependent nuclear factor of activated T cells (NF-AT) translocation to the nucleus, which is required for IL-2 transc...

Failure of androgen-targeted therapy and progression of castration-resistant prostate cancer (CRPC) are often attributed to sustained expression of the androgen receptor (AR) and its major splice variant, AR-v7. Although the new generation of anti-androgens such as enzalutamide effectively inhibits AR activity, accumulating pre-clinical and clinical evidence indicates that AR-v7 remains constit...

Following the first (1991-1993) and the second (1994-1996) TRMM PR teams, and the third international TRMM PR team (1997-2000), the fourth international TRMM PR team (2001-2003) started its job in 2001 based on the NRA-99-OES-03 in 1999 and NASDA-3rd RA-TRMM in 2000. In April 2004, the fourth international TRMM PR team completed the revisions of the standard algorithms to version 6. NASA and JA...

BACKGROUND The androgen receptor (AR) AR-V7 splice isoform is a constitutively active outlaw transcription factor. Transition of prostate cancer (PC) to the castration-resistant phenotype correlates with AR-V7 accumulation, suggesting that PC progression in patients refractory to conventional therapy is due to the activity of this AR isoform. The mechanism of AR-V7 constitutive activation is no...

This study aimed to investigate the role of AR-V7 in development of castration-resistant prostate cancer (CRPC) and to determine whether the AR-V7 expression in CRPC tissues can predict cancer-specific survival. We enrolled 100 localized prostate cancer (PCa) (cohort 1), 104 newly diagnosed metastatic PCa (cohort 2), and 46 CRPC (cohort 3) patients treated at our institution. The expression of ...

Castration-resistant (CR) prostate cancer (PCa) partly arises due to persistence of androgen receptor (AR) transcriptional activity in the absence of cognate ligand. An emerging mechanism underlying the CRPCa phenotype and predicting response to therapy is the expression of the constitutively-active AR-V7 splice variant generated by AR cryptic exon 3b inclusion. Here, we explore the role of the...

BACKGROUND The androgen receptor splice variant-7 (AR-V7) has been implicated in the development of castration-resistant prostate cancer (CRPC) and resistance to abiraterone and enzalutamide. OBJECTIVE To develop a validated assay for detection of AR-V7 protein in tumour tissue and determine its expression and clinical significance as patients progress from hormone-sensitive prostate cancer (...